Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

Canadian Journal of Cardiology

Volumn 22, Issue 2, 2006, Pages 141-144

  Simard, Chantale ^a,b   Poirier, Paul ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Ezetimibe; Monotherapy; Myalgia; Myopathy; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CREATINE KINASE; EZETIMIBE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; MALE; MONOTHERAPY; MYALGIA; MYOPATHY; PHARMACODYNAMICS; RECURRENT DISEASE; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG INTERACTION; METABOLISM; MIDDLE AGED; MUSCLE DISEASE; MUSCLE WEAKNESS; PAIN;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CREATINE KINASE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MUSCULAR DISEASES; PAIN;

EID: 33645237749     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70253-7     Document Type: Letter

References (22)

1. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-5.
2. Xydakis AM, Ballantyne CM. Combination therapy for combined dyslipidemia. Am J Cardiol 2002;90(10B):21K-9K.
3. Kosoglou T, Statkevich P, Meyer I, et al. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr Med Res Opin 2004;20:955-65.
4. Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004;93:1481-6.
5. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94.
6. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.
7. van Heek M, Farley C, Compton D, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134:409-17.
8. van Heek M, Farley C, Compton D, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-54.
9. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
10. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17.
11. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988;109:597-8.
12. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 1988;318:46-7.
13. Fux R, Morike K, Gundel UF, Hartmann R, Gleiter CH. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004;140:671-2.
14. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5.
15. Phillips PS. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004;141:649.
16. Carroll JE, Brooke MH, De Vivo DC, Kaiser KK, Hagberg JM. Biochemical and physiologic consequences of carnitine palmityltransferase deficiency. Muscle Nerve 1978;1:103-10.
17. Dulloo AG, Gubler M, Montani JP, Seydoux J, Solinas G. Substrate cycling between de novo lipogenesis and lipid oxidation: A thermogenic mechanism against skeletal muscle lipotoxicity and glucolipotoxicity. Int J Obes Relat Metab Disord 2004;28(Suppl 4):S29-37.
18. Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis 2004;177:183-8.
19. Simard C, Turgeon J. The pharmacokinetics of ezetimibe. Can J Clin Pharmacol 2003;10(Suppl A): 13A-20.
20. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-51.
21. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 2004;32:314-20.
22. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505-12.